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Abstract 
The oxidation-reduction (redox)–responsive micelle system is based on a diselenide-containing 
triblock copolymer, poly(ε-caprolactone)-bis(diselenide-methoxy poly(ethylene 
glycol)/poly(ethylene glycol)-folate) [PCL-(SeSe-mPEG/PEG-FA)2]. This has helped in the 
development of tumor-targeted delivery for hydrophobic anticancer drugs. The diselenide bond, 
as a redox-sensitive linkage, was designed in such a manner that it is located at the hydrophilic–
hydrophobic hinge to allow complete collapse of the micelle and thus efficient drug release in 
redox environments. The amphiphilic block copolymers self-assembled into micelles at 
concentrations higher than the critical micelle concentration (CMC) in an aqueous environment. 
Dynamic light scattering (DLS) and transmission electron microscopy (TEM) analyses showed 
that the micelles were spherical with an average diameter of 120 nm. The insoluble anticancer 
drug paclitaxel (PTX) was loaded into micelles, and its triggered release behavior under different 
redox conditions was verified. Folate-targeting micelles showed an enhanced uptake in 4T1 
breast cancer cells and in vitro cytotoxicity by flow cytometry and (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay, respectively. 
Delayed tumor growth was confirmed in the subcutaneously implanted 4T1 breast cancer in mice 
after intraperitoneal injection. The proposed redox-responsive copolymer offers a new type of 
biomaterial for drug delivery into cancer cells in vivo.  
 
Keywords: Redox-sensitive, Micelle, Diselenide, Breast cancer, Drug delivery 
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1. Introduction 
Over the past decades, substantial research in cancer therapy has led to the development of 
polymeric drug delivery systems (DDSs) [1]. Polymeric micelles are considered to be one of the 
suitable candidates for DDSs. The micelles are formed by self-assembly of amphiphilic block 
copolymers into a spherical supramolecular core/shell nanostructure [2]. Poorly water-soluble 
anticancer agents can be encapsulated by physical entrapment into the hydrophobic core of the 
polymeric micelles [3]. The hydrophilic shell acts as a hydration barrier to provide colloidal 
stability and prolong the circulation time of nanoparticles by preventing rapid clearance from the 
bloodstream and uptake by the reticuloendothelial system (RES) [4,5]. Polyethylene glycol 
(PEG) is often used as a hydrophilic block owing to its acceptable biocompatibility, protein 
repulsion, lack of toxicity, and immunogenicity [6]. The biodegradable and biocompatible 
polyesters such as polycaprolactone (PCL), poly(D,L-lactic acid) (PLA), polyglycolic acid 
(PGA), and poly(lactide-co-glycolic acid) (PLGA) have been introduced as hydrophobic blocks 
[7-9]. In 2007, paclitaxel (PTX)-loaded poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-PLA), 
termed Genexol-PM, was approved in Korea for the treatment of breast and mid-to-large–sized 
lung cancer cells [7]. Several other polymeric micelles have also entered clinical trials, such as 
NK105, NK911, NK012, and CriPec®-docetaxel [10]. Drug release in conventional micelles 
occurs by diffusion in addition to hydrolysis-induced biodegradation of the polyester micelles 
[11] and results in the nontargeted, insufficient, and uncontrolled release of the payloads. This 
inadequate accumulation of active drug within the cells leads to lack of therapeutic efficacy and 
drug resistance [12]. It is therefore necessary to increase the dosage of the administered drug to 
overcome this issue, and this often results in undesirable adverse effects. 
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Stimuli-responsive DDSs have attracted much attention recently owing to their potential for 
accurate and drug release in a controlled manner [13]. Among the mentioned stimuli such as pH 
[14], heat [15], oxidation–reduction (redox) potential [16], hypoxia [17], and enzymes [18], 
redox-responsive DDSs have demonstrated useful drug release behavior owing to the significant 
gradient in reducing potential among tumor and normal tissues. S-containing polymers, because 
of the reductive property of the sulfur (S) element, have proven to be ideal candidates for 
reductive-responsive disassembly for active anticancer drug release [19,20]. Shell-sheddable 
micelles, which contain a disulfide linkage between the hydrophilic and hydrophobic segments, 
have proven to exhibit a rapid intracellular drug release immediately after exposure to the 
reductive diseased region [21].  
Inspired by the success of disulfide bonds, selenium (Se), an element listed in the family same as 
that of S in the periodic table of elements (chalcogens), has recently attracted considerable 
attention for not only their reduction responsiveness but also their sensitivity to low 
concentrations of oxidative agents [22]. In fact, Se-containing polymers have increased 
sensitivity and rapid responses to stimuli compared to disulfide analogs because of the weaker 
bond energy of the C-Se (244 kJ/mol) and Se-Se (172 kJ/mol) bonds than that of the C-S (272 
kJ/mol) and S-S (240 kJ/mol) bonds [23,24]. Additionally, Se is involved in a wide range of 
biological functions such as antioxidant protection, thyroid function, gene transcription, cell 
growth, enhancement of the immune response, and anticancer activity [25–29]. Results indicate 
that the diselenide bond located between hydrophilic and hydrophobic segments is more 
preferred in case of diblock copolymers to ensure the complete collapse of a micelle when 
subjected to the redox stimuli, thus resulting in effective drug release [30]. It has also been 
shown that a diselenide bond is more sensitive than a disulfide bond, and the nanocarrier 
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containing diselenide has great potential for smart antitumor drug delivery [31]. Thus far, no 
studies have reported triblock copolymers with a diselenide linkage at the hydrophilic–
hydrophobic hinge, as a micelle component. 
In the following study, a dual reduction and oxidation (redox)–responsive triblock copolymer 
denoted as PEG-SeSe-PCL-SeSe-PEG [PCL-(SeSe-mPEG)2], which contained a diselenide 
linkage between the hydrophobic (PCL) and hydrophilic (PEG) segments, was synthesized. The 
redox-sensitive triblock copolymer self-assembled into shell-sheddable micelles with a spherical 
core-shell structure in water. Higher specificity for cancer cells toward existing copolymers can 
be achieved by targeting the folate receptor, which is overexpressed on cancer cells [32,33] 
(Scheme 1). The disassembly of micelles and release of encapsulated anticancer drugs in the 
presence of oxidants or reductants were examined. In addition, careful evaluations of their in 
vitro and in vivo  antitumor effects, cellular uptake, intracellular drug distribution, and systemic 
toxicity were performed. Our study concluded that the newly synthesized (PCL-(SeSe-mPEG)2) 
copolymer offers a promising type of micellar carrier for controlled drug delivery for cancer 
therapy.  
 
2. Materials and Methods 
2.1. Materials 
PCL diol (Mn=2000 Da); PEG methyl ether (mPEG, Mn=2000 Da); 3,3-dithiodipropionic acid 
(DTPA); N,N-dicyclohexylcarbodiimide (DCC); 4-(dimethylamino)pyridine (DMAP); 
triethylamine (TEA); chloroform; ammonium sulfate (AS); DL-Dithiothreitol (DTT); ethanol 
(EtOH); diethyl ether; and methanol were purchased from Merck (Germany). L-Glutathione 
(GSH); Se; trypsin-EDTA; dimethyl sulfoxide (DMSO); anhydrous tetrahydrofuran (THF); 
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sodium borohydride (NaBH4); dimethylformamide (DMF); p-toluenesulfonyl chloride; hydrogen 
peroxide (H2O2); ammonia solution; 10-bromodecanoic acid 95%; dichloromethane (DCM); 
hexane; Hoechst 33342; Ca
2+
-free and Mg
2+
-free Dulbecco's phosphate-buffered saline (DPBS); 
phosphate-buffered saline (PBS); 4-(2-hydroxy-ethyl)-1-piperazineethane sulfonic acid 
(HEPES); deuterochloroform (CDCl3); coumarin-6; 4′,6-diamidine-2′-phenylindole 
dihydrochloride (DAPI); Di-tert-butyldicarbonate (Boc2O); folic acid (FA); magnesium sulfate 
(MgSO4); dialysis tubing (MWCO=3500 Da); DCC; trifluoroacetic acid (TFA); and PTX were 
purchased from Sigma (St. Louis, MO, USA). RPMI-1640 medium and Alexa 488 dye were 
purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS); RPMI-1640 
(without folic acid); penicillin; L-glutamine; and streptomycin were obtained from Gibco BRL 
(Rockville, MD, USA). A CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit 
[containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) and phenazine methosulfate (PMS)] was obtained from Promega (Madison, 
WI, USA). Ki-67 antibody (Abcam 15580) was purchased from Abcam (Cambridge, MA, USA). 
All other chemicals were of reagent grade and used as received.  
 
2.2. Characterization 
Fourier-transform infrared spectroscopy (FTIR) data were recorded on a PerkinElmer (RX I, 
USA) Fourier spectrometer at wavenumbers of the range 4000–400 cm
-1
 according to the KBr 
disk method. 
1
H NMR spectra were acquired on a Bruker and Varian (400 mHz, Germany) NMR 
spectrometer. 
77
Se-NMR measurements were acquired on a 500-MHz-Bruker-AV3-NMR 
spectrometer. The molecular weight (MW) was determined by gel permeation chromatography 
(GPC) (Agilent 110 HPLC, USA). Drug release profile was assessed using a high-performance 
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liquid chromatography (HPLC; Shimadzu, LC-10AT, China) system. Acetonitrile/water (50:50, 
v/v) was used as the mobile phase at 30°C with a flow rate of 1.0 mL/min. UV–Vis spectra were 
recorded using a Rayleigh UV-2601 (Beijing Rayleigh Analytical Instrument Co., Rayleigh UV-
2601, China). The UV–Vis detector was set at 227 nm and linked to Breeze software for data 
analysis. Size distribution of micelles in aqueous solution was measured from three batches for 
each group in triplicates, using dynamic light scattering (DLS) carried out on a Malvern (Nano 
ZS90, UK) with a He–Ne laser (633 nm) and a scattering angle of 90°. Transmission electron 
microscopy (TEM) was performed using a JEM-2000CX, (JEOL Ltd., Japan) transmission 
electron microscope that had an accelerating voltage of 15 kV. The samples were prepared by 
pipetting a drop of the micelle solution (1 g/L) onto 230 carbon-coated mesh copper grids. The 
samples had to be air-dried before obtaining the measurements. The critical micelle 
concentration (CMC) of the PCL-(SeSe-mPEG)2 copolymer in water was determined by using 
pyrene as the fluorescence probe in a Hitachi F-4500 fluorescence spectrophotometer (F-4500, 
Hitachi, Japan). 
 
2.3. Synthesis and characterization of block copolymers 
2.3.1. Synthesis of diselenide 
Diselenide was prepared as previously described (Fig. 1A) [34]. Briefly, elemental Se (0.157 g, 
1.99 mmol) and NaBH4 (0.152 g, 3.98 mmol) were placed in a two-neck round-bottom flask and 
mixed under nitrogen gas flow. Then, 98% EtOH (0.7 mL) was added to the mixture until 
complete dissolution of Se and the formation of a white–gray solid. Subsequently, DMF (4 mL) 
was added to the solution, and this solution was then stirred until the formation of a red–brown 
color. Commercial 80% EtOH (0.45 mL) was continuously added to the mixture and vigorously 
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stirred until the end of gas production. Se powder (0.157 g, 1.99 mmol) was then added to the 
solution and stirred until the powder completely dissolved and a clear dark red solution was 
observed. Then, 10-bromodecanoic acid (1 g, 3.98 mmol) was added to the solution, thus 
resulting in a color change from red to yellow. After 24 h, the reaction was stopped by the 
addition of water (12 mL). The reaction mixture was extracted with diethyl ether (3×10 mL), and 
the extracted organic phase was washed with water (3×20 mL) and brine (15 mL). The organic 
phase was dried over MgSO4 and filtered. The solvent was completely evaporated, and a yellow 
powder was obtained as the  with the following specifications: yield: 65%; 
1
H NMR 
(CDCl3, 400 MHz, δ): 1.22 (m, 20H, -CH2), 1.50 (m, 4H, -CH2CH2Se-), 1.6 (m, 4H, -
CH2CH2COOH), 2.2 (t, 4H, -CH2Se-), and 2.8 (t, 4H, -CH2COOH) (Figure 3A, B). 
77
Se-NMR 
(1H-decoupled, THF-d8, 500 MHz): 303(s, Se2). 2D 
1
H,
77
Se-HMBC (THF-d8, 500 MHz) 
(Figure 2A, B). 
 
2.3.2. Synthesis of PCL-(SeSe-COOH)2 
HOOC-SeSe-PCL-SeSe-COOH (PCL-(SeSe-COOH)2) was generated as follows. The PCL diol 
was allowed to react with excess diselenide by an esterification reaction (Fig. 1B). Briefly, a 
solution of DCC (1 mmol, 0.2 g) and DMAP (1 mmol, 0.12 g) were dissolved in THF (5 mL) 
and slowly dropped into a solution of PCL diol (0.1 mmol, 0.2 g) and diselenide (0.5 mmol, 0.25 
g), dissolved in THF (5 mL). TEA (0.05 mL) was added to the reaction as a catalyst. The 
reaction was performed at room temperature (RT) under N2 for 2 days. The polymer solution was 
filtered to remove DCU and concentrated by rotary evaporation. The concentrated filtrate was 
precipitated twice in diethyl ether. This precipitate was vacuum dried and had the following 
specifications: yield: 78%; 
1
H NMR (CDCl3, 400 MHz): δ 1.22 (m, 20H, -CH2), 1.36 (m, 2H, 
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COCH2CH2CH2CH2CH2O), 1.65 (m, 4H, -CH2CH2O), 2.31 (t, 2H, -CH2COO-), and 4.06 (t, 2H, 
-CH2O-) (Figure 3C). 
 
2.3.3. Synthesis of the mPEG-amine 
TEA (800 µl) was added to a solution of mPEG-OH (1 mmol, 2 g) in DCM (10 mL). p-
Toluenesulfonyl chloride (1.99 mmol, 0.38 g) was then added in DCM (1 mL) dropwise to the 
vigorously stirred mixture. The reaction mixture was allowed to stir at RT overnight, after which 
this mixture was washed twice with a solution of NH4Cl (500 mL). The organic phase was 
separated and dried over anhydrous MgSO4. The solvent evaporated under pressure. The mPEG-
OTs, as the solid product, were precipitated in diethyl ether and allowed to dry overnight in a 
vacuum oven. The dried product had the following specifications: yield: 83%; 1H NMR (CDCl3, 
400 MHz): δ 2.37 (d, 4H, s, 6H, -CCH3), 3.55 (m, 181H, PEG backbone, -OCH2-), 4.08 (t, 4H, -
CH2OTs), and 7.35-7.80 (d, 8H, aromatic ring) (Figure 3D). 
mPEG-amine was prepared by dissolving 1.5 g of mPEG-OTs in an ammonia solution (80 mL), 
and this solution was stirred for 5 days at RT. The organic phase was separated and washed twice 
with DCM. The organic phase was dried over anhydrous MgSO4, filtered, and evaporated under 
pressure. The concentrated filtrate was precipitated with cold diethyl ether, and the obtained 
mPEG-NH2 was vacuum dried (white solid, 88%). The ninhydrin reaction was used to test for the 
presence of the amino group. The results indicated a yield of 78%; 
1
H NMR (CDCl3, 400 MHz, 
δ): 1.93 (broad peak, 4H, -NH2), 3.42 (t, 4H, end -OCH2- group), 3.67 (s, 181H, PEG backbone, 
-OCH2-) (Figure 3E). PEG diamine (NH2-PEG-NH2) was also prepared by the same method. 
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2.3.4. Synthesis of PCL-(SeSe-mPEG)2 
PCL-(SeSe-mPEG)2 was synthesized by an amide formation reaction between carboxyl groups of 
the synthesized PCL-(SeSe-COOH)2 polymers and the amine group of mPEG-NH2 (Fig. 1B). 
Briefly, PCL-(SeSe-COOH)2 (0.04 mmol, 0.12 g) and mPEG-NH2 (0.12 mmol, 0.24 g) polymers 
were dissolved in chloroform (15 mL). A solution of DCC (0.09 mmol, 0.018 g) and NHS (0.09 
mmol, 0.01 g) dissolved in chloroform (5 mL) was added to the polymer solution. The coupling 
reaction between mPEG-NH2 and PCL-(SeSe-COOH)2 was carried out for 2 days at RT and 
under N2 atmosphere. We filtered the copolymer solution to remove DCU, and the filtrate was 
slowly dropped into cold diethyl ether to precipitate the product as a white powder. The 
precipitate was vacuum dried at 30°C for 24 h. The dried product was dissolved in DMF and 
dialyzed against deionized water (DIW) with a dialysis membrane (MWCO=3.5 kDa) for 3 days. 
The dialyzed solution was lyophilized, and a white solid was obtained (Yield: 67.4%). 
1
H NMR 
(CDCl3, 400 MHz): δ 1.22 (m, 20H, -CH2), 1.31 (m, 2H, COCH2CH2CH2CH2CH2O), 1.57 (m, 
4H, -CH2CH2O), 2.24 (t, 2H, -CH2COO-), 3.58 (s, 181H, PEG backbone, -OCH2-), and 3.98 (t, 
2H, -CH2O-)] (Figure 3F). 
 
2.3.5. Synthesis of folate-conjugated block copolymer PCL-(SeSe-PEG-FA)2 
First, the PEG-diamine (NH2-PEG-NH2) was synthesized as described for mPEG-NH2. One 
amine end group was protected with Boc2O based on a previous report [35]. This copolymer had 
the following specifications: 
1
H NMR (CDCl3, 400 MHz, δ): 1.44 (S, 9H, -CH3) and 3.64 (s, 
181H, PEG backbone, -OCH2-) (Figures 1C and S2A).  
NH2-PEG-NHBoC (0.87 mmol, 0.216 g) was allowed to react with FA (0.75 mmol, 0.330 g) in 
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the presence of dicyclohexyl carbodiimide (2 mmol, 0.41 g) in 30 mL of anhydrous 
DMSO/pyridine (3:1). The reaction proceeded at RT under N2 atmosphere for 24 h. The resultant 
precipitate was filtered. The filtrate was then poured into a solution of cool diethyl ether to 
precipitate the product as a yellow powder. The precipitate was collected and dried under 
reduced pressure yielding FA-PEG-NHBoC. FA-PEG-NHBoC was unprotected by the reaction 
with TFA. Briefly, FA-PEG-NHBoC (0.045 mmol, 0.01 g) was dissolved in TFA (2 mL) and 
stirred for 3 h. TFA was completely removed under reduced pressure after which the residue was 
dissolved in DCM and precipitated in cold diethyl ether. The precipitate was collected and dried 
under reduced pressure to yield FA-PEG-NH2 with the following specifications: 
1
H NMR 
(CDCl3, 400 MHz, δ): 3.57 (s, 181H, PEG backbone, -OCH2-), 6.5, 6.7, 7.6, 7.7 (benzene ring), 
6.9 (s, aromatic H of pteridine), and 8.7 (s, OH, 1H) (Figures 1C and S2B). 
PCL-(SeSe-PEG-FA)2 was synthesized by an amide bond formation reaction between the amine 
group of FA-NH-PEG-NH2 and carboxyl groups of PCL-(SeSe-COOH)2, as described for the 
PCL-(SeSe-mPEG)2 preparation. 
 
2.3.6. Synthesis of mPEG-PCL-mPEG 
mPEG-PCL-mPEG copolymer was synthesized and used a control polymer. Initially, COOH-
PCL-COOH was synthesized by a reaction of PCL diol with succinic anhydride. Briefly, PCL 
diol (1 g, 0.5 mmol) and succinic anhydride (0.4 g, 4 mmol) were added to dried dioxane (10 
mL) and stirred until all reactants completely dissolved. DMAP (0.49 g, 4 mmol) and TEA (0.56 
mL, 4 mmol) were added to the reaction mixture. The reaction was stirred for 24 h at RT under 
N2 atmosphere. The solvent was evaporated in a rotary evaporator after which the concentrated 
cure product was precipitated in cold diethyl ether. This product had the following specifications: 
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yield: 89%.
1
H NMR (CDCl3, 400 MHz): δ 1.34 (m, 35H, -COCH2CH2CH2CH2CH2O-), 1.56 (m, 
70H, -COCH2CH2CH2CH2CH2O-), 2.31 (t, 35H, - COCH2CH2CH2CH2CH2O-), 2.57 (m, 70H, -
COOCH2CH2COOH), 4.06 (t, 35H, -COCH2CH2CH2CH2CH2O-)] (Figure S2C).  
Terminal carboxyl groups of HOOC-PCL-COOH were reacted with the amine group of mPEG-
NH2 by a coupling reaction as described for the PCL-(SeSe-mPEG)2 preparation (Yield: 81.3%). 
 
2.4. Preparation of micelles 
The amphiphilic block copolymers (5 mg) were dissolved in DMF (2.5 mL) under vigorous 
stirring. The resultant solution was dialyzed against DIW by a dialysis membrane (MWCO=3.5 
kDa) for 24 h, in which water replaced the DMF and the copolymers could self-assemble into 
nanomicelles. After 24 h, the dialyzed solution was filtered with a 0.45-µm filter and lyophilized. 
 
2.5. Preparation of paclitaxel (PTX)-loaded micelles 
PTX-loaded polymeric micelles were prepared according to the membrane dialysis method [36]. 
Briefly, PTX (5 mg) was added to the polymer solution (25 mg in 10-mL DMF) and stirred for 3 
h at RT. The solution was then dialyzed against DIW for 24 h to remove the organic solvent and 
any unloaded PTX. The drug-loaded nanoparticle (NP) solution was filtered by a 0.45-µm filter 
to remove unloaded PTX. The PTX-loaded micelles were then freeze-dried.     
Drug loading content (DLC) and drug loading efficiency (DLE) of these micelles were 
determined by HPLC according to previously reported procedures [37]. Briefly, drug-loaded 
micelles (5 mg) were dissolved in 1-mL DMF under vigorous vortexing. This solution was 
transferred to 5 mL of a mobile phase that consisted of DIW and acetonitrile (50:50, v/v). The 
samples were left overnight in a vacuum oven to evaporate water. Four hundred milliliters of 
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60% acetonitrile were added to the samples for HPLC analysis. A reverse-phase C
18 
column (250 
mm x 4.6 mm; Agilent Technologies) was used with a flow rate of 1 mL/min for the mobile 
phase. The column effluent was detected at 227 nm using an UV-Vis detector. We calculated 
both DLC and DLE according to the following equations: 
 
 
 
2.6. In vitro L-Glutathione (GSH)- and hydrogen peroxide (H2O2)-triggered release of 
paclitaxel (PTX) from micelles 
In vitro release profiles of PTX from micelles were investigated in three different buffers (all 
containing 1 M sodium salicylate) of PBS (0.01 mol/L, 1 M sodium salicylate, pH 7.4), 2 mM 
GSH, and 0.1 wt. % H2O2 by the diffusion technique using a dialysis bag [34]. Drug-loaded 
micelles (1.5 mL) were introduced into a dialysis membrane tubing (Spectra, MWCO=3.5 kDa) 
and incubated in 25 mL of buffer at 37°C. At predetermined time intervals, samples were drawn 
from each buffer and replaced with an equal volume of the same medium. The concentration of 
PTX in the solution was measured by HPLC as previously described. 
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2.7. Cell culture 
Murine breast cancer cell line 4T1 (Cell Bank, Pasteur Institute of Iran) was cultured in RPMI-
1640 with 5 g/L L-glutamine supplemented with 10% FBS, 100 U/mL of penicillin, and 100 
mg/mL streptomycin. The cells were incubated at 37°C under humidified 5% CO2 atmosphere. 
Passage-2 cells were used for all in vitro analyses. All cell studies were conducted in folic-acid 
free media except for competition studies were folic acid was added at 100 µg/ml. 
 
 
2.8. Cytotoxicity and in vitro antitumor efficacy of micelles 
MTS assay was used to evaluate the material cytotoxicity of the generated micelles in 4T1 cells. 
4T1 cells were cultured in folate-free RPMI-1640 media 2 weeks before the cytotoxicity test was 
performed. A ready-for-use CellTiter 96
®
 aqueous solution was used according to the 
manufacturer’s protocol. 4T1 cells were seeded at a density of 5×103 cells/well and allowed to 
incubate for 24 h [38]. Then, the culture medium was replaced by 120 µL of the freshly prepared 
culture medium containing Taxol

, PCL-(SeSe-mPEG)2, PCL-(SeSe-PEG-FA)2, PTX-loaded 
PCL-(SeSe-mPEG)2, or PTX-loaded PCL-(SeSe-PEG-FA)2 micelles with equivalent 
concentrations that ranged from 0.01 to 1000.0 nM. After 24 h, the culture medium was removed 
and cells were rinsed with PBS. MTS stock solution (20 µL/well of MTS and 100 µL/well of cell 
media) was added to each well, cells were incubated for an additional 2 h, and absorbance was 
then measured at 490 nm by using a microplate reader (SpectraMax, M5, Sunnyvale, CA, USA) 
to calculate cell viabilities. The IC50 values were obtained by nonlinear regression curve-fit of 
the cell viability data with GraphPad Prism Software 7.0 (GraphPad Software, Inc., La Jolla, CA, 
USA). 
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2.9. Cellular uptake and intracellular drug release of coumarin-6–loaded micelles 
The cellular uptake and intracellular drug release of loaded micelles were evaluated by loading 
coumarin-6 as a hydrophobic fluorescence marker for flow cytometry and confocal laser 
scanning microscopy (CLSM) analyses [39]. 
For flow cytometry analysis, 4T1 cells, maintained in folate-free RPMI-1640 media, were 
subcultured in a six-well plate (5×10
4
 cells/well) for 24 h, followed by treatment with coumarin-
6–loaded PCL-(SeSe-mPEG)2 or coumarin-6–loaded PCL-(SeSe-PEG-FA)2 at a final coumarin-6 
concentration of 12.5 μg/mL. The free coumarin-6 was used as control at a concentration same as 
that of the coumarin-6 loaded in the micelle (12.5 μg/mL). Cells were subsequently rinsed thrice 
with PBS and harvested with trypsin, resuspended in PBS, and measured for fluorescence 
intensity (excitation: 450 nm, emission: 480 nm) on a BD FACSCalibur flow cytometer (Becton 
Dickinson, New Jersey, USA). The cellular uptake efficiency was calculated as follows: 
 
where Isample, Ipositive, and Inegative represent the fluorescence intensities of the sample, positive 
(coumarin-6–loaded NPs in the cell lysis solution) control, and negative control (blank cell lysis 
solution), respectively. In this experiment, each particle suspension was added to five wells to 
study the effect of cellular uptake at 0.5- to 4-h time intervals.  
For CLSM observation, 4T1 cells were seeded in 12-well glass-bottomed plates at a density of 
1×10
5
 cells/well in 1.5 mL of folate-free RPMI-1640 media and cultured for 24 h to reach an 
80% confluence. The cells were then treated with coumarin-6–loaded PCL-(SeSe-mPEG)2 or 
coumarin-6–loaded PCL-(SeSe-PEG-FA)2, where the final concentration of coumarin-6 inside 
the micelle was maintained at 12.5 μg/mL. The free coumarin-6 was also used at a concentration 
of 12.5 μg/mL for 4 h [40]. Cells were rinsed thrice with PBS and fixed with 4% 
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paraformaldehyde for 20 min at RT. Finally, the nuclei were stained with Hoechst 33342 (10 
µg/mL) in the culture medium for 10 min. The slides were mounted and observed by a confocal 
laser scanning microscope (Leica, TCS SP8, USA) equipped with excitation lasers (408 nm for 
the diode and 543 nm for He-Ne) and variable bandpass emission filters. All fluorescence images 
were captured using a microscope with the same setting parameters that included the intensity of 
the exciting light and exposure time for microscopy. 
 
2.10. Animal study  
2.10.1. 4T1 xenograft mice model  
4T1 cells (5×10
6
/100 µL of culture medium) were subcutaneously inoculated in the exponential 
phase of growth into the right flanks of 4-week-old (18–20 g) female BALB/c mice.  
Mice were randomized into one of four experimental groups (n=6 per group) when tumors 
reached an average volume of 100 mm
3
 [41]. Naked drug group was administered Taxol®, 
which was prepared by mixing a suspension of Taxol® in saline to create a 1.5-mg/mL PTX 
solution. All treated mice received intraperitoneal (i.p.) injections of Taxol®, PTX-loaded PCL-
(SeSe-mPEG)2, PTX-loaded PCL-(SeSe-PEG-FA)2 at a PTX dosage of 15 mg/kg. The group 
injected with normal saline was assigned as a control. Treatments were administered every 4 
days for six cycles as suggested in previous studies [42]. Tumor size was measured every 2 days 
using calipers for a 30-day period. Tumor volume was calculated as follows:  
Tumor volume (mm
3
) = 0.5 × (L × W
2
) 
where L and W are the length of major axis and width of minor axis, respectively. The Royan 
Animal Ethical Committee approved the animal study procedures. 
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2.10.2. Histology and immunohistofluorescence assay 
Mice were euthanized on day 30. Tumor tissues were collected immediately, fixed in 4% 
paraformaldehyde for at least 24 h, and maintained in 30% sucrose/PBS until sectioning. The 
tumors were sliced with a thicknesses of 16 µm and stained with hematoxylin and eosin (H&E) 
for evaluation of any histopathological changes. The Ki-67 (1:100 dilution) antigen staining 
assay was conducted to evaluate antitumor efficacy on cell proliferation according to the 
manufacturer’s protocol. In summary, the tissue sections were permeabilized with Triton X-100 
and incubated with the antibody diluted in blocking buffer for 16 h. The cell nuclei were stained 
with DAPI (1.5 µg/mL of PBS solution) for 5 min. Paraffinized sections of organ tissues such as 
the lungs, heart, spleen, and kidneys were dewaxed in xylene, passed through a graded series of 
alcohol, rinsed in distilled water, and stained with H&E. 
H&E- and Ki-67-stained sections were observed under a microscope (X51 Olympus; Olympus 
Corp. Tokyo, Japan). The extent of inflammatory changes that included macrophage and 
neutrophil localization, loss of blood, myofibrillar loss, cell atrophy, and fibrosis were assessed 
by a board-certified pathologist who had no knowledge of the study group assignments. 
The apoptotic index was measured using the morphometric cell count (MCC) analysis that 
reports the apoptotic index as the total number of apoptotic cells versus the total number of 
cancer cells. Cell counts were performed by Image-Pro Plus 6.0 (Media Cybernetics, Inc., USA). 
The proliferation index was measured by the method same as that for apoptotic index, with the 
difference of reporting total numbers of proliferated cells (stained green cells in images) versus 
total numbers of cancer cells.  
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2.10.3. Myelosuppression and enzyme activity assay  
Serum white blood cell (WBC) counts were assessed to study bone marrow suppression induced 
by the micelles. The blood samples were collected twice from each mouse (approximately 0.5 
mL), once before starting the treatment and once on day 30 before they were sacrificed. WBCs 
were counted with the MEK-6318K Automated Hematology Analyzer (Nihon Kohden Corp., 
Japan).  
Liver toxicity of the formulations was determined according to levels of the liver-specific 
enzymes serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic 
transaminase (SGPT). Serum SGOT and SGPT levels were determined using an autoanalyzer 
(Technicon RA1000 analyzer; Technicon Instruments, NY, USA) [43]. 
 
2.11 In vivo CT and ultrasound imaging of the tumor model 
CT imaging was performed on a SOMATOM Spirit (Siemens, Berlin, Germany) scanner with 
the following parameters: beam collimation: 2 x 1 mm, beam pitch: 0.5 mm, gantry rotation 
time: 0.8 s, slice thickness: 1 mm, Kernel: (U 90) ultra-high resolution, and window: Osteo. All 
in vivo groups of 4T1 tumor-bearing mice were imaged. Evaluation of images was performed by 
loading the digital CT images in a standard display program (DICOM viewer) after which a 
uniform round region of interest in the CT image was selected for each sample. CT imaging was 
performed to measure the thoracic and abdominal cavities of each mouse at day 30. 
Ultrasound images were acquired by using a GE Voluson 730 Pro (GE, Milan, Italy) ultrasound 
machine with a linear and phased array with a 7- to 12-MHz probe with a near-field setting. Data 
from dorsal recumbency under general anesthesia were obtained from female BALB/c 4T1 
tumor-bearing mice at day 30.   
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2.12 Statistical analysis  
Data were analyzed using GraphPad Prism version 6.01 (GraphPad Software, San Diego, CA, 
USA). Each experiment was repeated at least thrice unless otherwise noted. The mean value of 
the repetition was calculated and used for statistical analysis. For multiple groups, results were 
analyzed by one-way analysis of variance (ANOVA) followed by the Newman−Keuls test. A p-
value of <0.05 was considered statistically significant (*p<0.05, **p<0.01, ***p<0.001). 
 
3. Results and discussion 
3.1 Synthesis and chemical characterization of the copolymers  
Wei et al prepared a diselenide-centered biodegradable triblock copolymer (mPEG–PCL–Se)2 
that enabled the formation of self-assembled micelles [44]. In the previously reported study, the 
diselenide linkage was located in the core of the micelle, i.e., within the hydrophobic PCL chain 
and not at the PEG-PCL junction. The mechanism of drug release in the previous study is 
believed to occur through formation of pores of increasing sizes causing release of the anticancer 
drugs in a simulated tumor microenvironment. The use of shell-sheddable micelles may offer a 
more efficient stimuli-responsive drug release strategy, with drug release occuring as a result of 
micelle shell collapse [30]. In this study, we prepared a diselenide-bearing triblock copolymer in 
an attempt to develop a smart shell-sheddable micelle with sensitivity to redox environments. 
The proposed micelle has a hydrophilic outer shell that consists of mPEG, a hydrophobic core 
composed of PCL, and diselenide bonds located between the inner hydrophobic core and outer 
hydrophilic shell. This micelle can undergo shell shedding by breaking the diselenide bonds in a 
redox environment and subsequently release its payload. Figure 1 shows the synthesis of the 
copolymer. Initially, the bis(decanoic acid)-diselenide (diselenide) was synthesized by using 10-
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bromodecanoic acid. Owing to solubility issues, we first introduced the diselenide group onto a 
long alkyl chain with carboxyl end groups, which possessed the desirable solubility in organic 
solvents [24]. The diselenide-containing amphiphilic block copolymer PCL-(SeSe-mPEG)2 was 
then synthesized by a coupling reaction of PCL-diol with an excess amount of diselenide and 
finally terminated by PEG monomethyl ether and/or folate-conjugated PEG (Fig. 1).   
1
H-NMR and FTIR spectra were obtained to confirm the chemical structures of the synthesized 
polymers. Figures 2 and 3 as well as Supplementary Figures S1 and S2 show the assigned 
characteristic peaks of the products. In the first step, diselenide was synthesized by a reaction 
between 10-bromodecanoic acid and Se powder in the presence of NaBH4. 
1
H-NMR confirmed 
the formation of bis(decanoic acid)-diselenide by shifting the peak at 3.40 ppm related to –CH2-
Br of 10-bromodecanoic acid to 2.86 ppm related to –CH2-Se- of bis(decanoic acid)-diselenide 
(Fig. 3A,B). Further, 
77
Se-NMR showed one clean peak at 303 ppm, related to Se-site (Figure 
2A). In addition, the 2D 
1
H,
77
Se-HMBC indicated the presence of 
77
Se attached to decanoic acid 
(Figure 2B). On the basis of the analysis conducted, it was confirmed that the diselenide 
compound was successfully synthesized. In the next step, PCL-(SeSe-COOH)2 was synthesized 
by an esterification reaction of diselenide carboxyl groups and the hydroxyl end groups of the 
PCL-diol. The successful synthesis of PCL-(SeSe-COOH)2 was confirmed by the characteristic 
peaks of methylene protons in PCL blocks at 1.40 ppm (-COCH2CH2CH2CH2CH2O-), 1.54 ppm 
(-COCH2CH2CH2CH2CH2O-), 2.25 ppm (-COCH2CH2CH2CH2CH2O-), and 3.97 ppm (-
COCH2CH2CH2CH2CH2O-) as shown in Figure 3C. The FTIR spectrum of PCL-(SeSe-COOH)2 
(Fig. S1) showed one band at 1734 cm
-1
, which was related to -COO- band stretching vibrations 
in PCL. The broad band at 2500-3400 cm
-1
 was assigned to the terminal carboxyl groups of the 
diselenide segments. FTIR spectrum exhibited characteristic peaks of both diselenide and PCL 
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segments, which further confirmed the success of this synthesis (Fig. S1a). To add PEG as a 
hydrophilic block to the end of PCL-(SeSe-COOH)2, the mPEG-NH2 was synthesized in two 
steps by using PEG as an initiator. Initially, mPEG-OTs was synthesized by using mPEG-OH 
and p-toluene sulfonyl chloride. Next, mPEG-OTs was converted to mPEG-NH2 by the addition 
of aqua ammonia by stirring. 
1
H NMR spectra confirmed the successful preparation of mPEG-
OTs and mPEG-NH2 by showing the characteristic peaks of –CH2-OTs and -CH2-NH2, 
respectively (Fig. 3D, E). Figure S1b shows the FTIR spectrum of mPEG-NH2. Finally, PCL-
(SeSe-mPEG)2 with two separate diselenide groups in the hydrophobic–hydrophilic interface of 
the copolymer was prepared by the introduction of mPEG-NH2 into the carboxyl end groups of 
(PCL-SeSe-COOH)2 by an amide formation reaction. The appearance of a characteristic peak at 
3.60 ppm was related to the methylene groups of PEG. The presence of characteristic peaks for 
PCL-(SeSe-COOH)2 in the 
1
H NMR spectrum of PCL-(SeSe-mPEG)2 (Fig. 3F) showed the 
successful PEGylation of PCL-(SeSe-COOH)2. FTIR spectrum analysis of the final PCL-(SeSe-
mPEG)2 also showed characteristic peaks of both PCL-(SeSe-COOH)2 and mPEG-NH2 
segments, which demonstrated successful synthesis (Fig. S1c). The MW of PCL-(SeSe-mPEG)2 
was determined by GPC with experimental MW of 10,000 g/mol which is in close agreement 
with the theoretical value of 8500 g/mol (Fig. S5). In the GPC data, a clear secondary peak at a 
higher MW was observed, which could have been caused by the formation of an undesirable side 
product. For example, one possibility is that in the stage of PCL-(SeSe-COOH)2 synthesis, a 
diselenide residue contributed to the formation of two or more PCL(Se-Se-mPEG)2 adducts in 
the subsequent reaction. The amount, however, deemed to be negligible. 
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3.2. Preparation of micelles 
The PCL-(SeSe-mPEG)2 amphiphilic block copolymer formed core-shell–type micelles by self-
assembly when exposed to an aqueous environment. The CMC of the amphiphilic PCL-(SeSe-
mPEG)2 copolymer was determined by fluorescence spectroscopy using pyrene as a hydrophobic 
probe molecule [45]. For fluorescence spectroscopy, the pyrene concentration in the final 
solutions was fixed at 6.0×10
-7 
mol/L, whereas the concentrations of the PCL-(SeSe-mPEG)2 
micelle varied from 5×10
-4
 to 5×10
-1
 mg/mL. The fluorescence intensity ratio of I372/I384, as a 
function of concentration was plotted to evaluate the CMC of the micelles prepared from 
copolymer PCL-(SeSe-mPEG)2 (Fig. 4A(I)) [46]. As shown in Figure 4A(II), the CMC value of 
micelles was calculated to be 0.035 mg/mL. This CMC value guaranteed that the self-assembled 
micelle could retain its original morphology under highly diluted conditions in vivo before 
reaching the target site. 
We evaluated the sizes of the micelles by dynamic light scattering (DLS). The results of DLS 
showed that PCL-(SeSe-mPEG)2 copolymers formed micelles with an average size of 140 nm 
and polydispersity index (PDIs) of 0.2. Decorating micelles with folic acid did not change their 
size significantly as shown in the DLS and TEM data (Fig. S9). The mean zeta potential was 
approximately -0.1 mV. The PCL-(mPEG)2 control group, without the diselenide linkage, was 
110 nm and had a -0.05-mV zeta potential (Fig. 4B). The size and morphology of the micelles 
were further evaluated by TEM. As shown in Figure 4C, the micelles had a spherical 
morphology with an average diameter that ranged from 110 to 140 nm. We observed that the 
NPs were well separated from each other, which indicated that there was no aggregation between 
the micelles.  
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3.3. Redox-sensitivity of blank micelles 
We designed this delivery system to be sensitive to both oxidative-rich and thiol-rich 
environments to fulfill the demand for clinical applications to release the drug in the intracellular 
region of cancerous cells. GSH, a thiol-containing chemical in the body, is present at a 100-1000 
times greater concentration in the intracellular matrix compared to that in the extracellular 
environment [47]. The concentration of H2O2, as a reactive oxygen species (ROS) agent, in the 
intracellular region of cancer cells can increase to approximately 100 times higher levels than 
that in normal cells [48]. The size changes of the micelles during time were monitored by DLS in 
redox solutions to evaluate their redox-triggered disassembly. As shown in Figure 4B, the 
micelles maintained structural integrity in the redox-free buffer solution with no significant 
change in particle size for 4 h. However, we observed that diselenide-bearing micelles incubated 
in 2 mM GSH or 0.1% wt. H2O2 solutions created particles of various sizes. The obvious change 
in the size indicated that diselenide-bearing micelles dissembled into irregular particles owing to 
the cleavage of diselenide bonds by GSH and/or H2O2, which confirmed the sharp response of 
these micelles to the redox environment. The control micelles that lacked diselenide bonds 
maintained their structural integrity, with a diameter size of approximately 100 nm after 
incubation with 2 mM GSH for 4 h (Fig. 4B), which provided strong evidence that the redox 
sensitivity of micelles was attributed to the diselenide bonds.  We also studied the cumulative 
release of carriers containing diselenide and folic acid to see whether conjugation to folic acid 
would affect the release pattern. For PCL-(SeSe-PEG-FA)2, we observed a similar pattern to 
PCL-(SeSe-mPEG)2 in 2 mM GSH and 0.1% H2O2 (not shown). This indicates that the inclusion 
of folic acid has no negative influence of the responsiveness of the diselenide-containing system.   
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3.4. Drug loading and release of micelles  
We used the dialysis protocol to prepare the drug-loaded micelles. Hydrophobic anticancer PTX 
was readily integrated into the micellar core through hydrophobic interactions, and the excess 
PTX was removed by extensive dialysis. The theoretical DLC of the micelles was 21%. 
However, we calculated a DLE of 75%, as described earlier. Our DLC value is in agreement 
with those in the studies reported by others including Kim Yeon et al [49] and Wei Xiong et al 
[50], with reported values in the range of 16-20%. Our DLE of 80% is also in line with those in 
the studies by Jian Gong et al [51] and Zachar L. Tyreell et al [52]. 
 
To study the oxidative and reductive responsiveness of micelles, we investigated the release 
behavior of PTX-loaded micelles by using a dialysis tube containing micelles in three different 
buffer solutions (2 mM GSH, 0.1 wt. % H2O2, and PBS). The results showed that the PTX 
release rate from the micelles that contained diselenide significantly (p<0.01) increased in the 
redox environment compared to the control group (Fig. 5A). Approximately 75% of PTX was 
released from the diselenide-containing micelles with and without folic acid decoration, within 
the first 24 h, when exposed to 2 mM GSH buffer. Drug release reached nearly 100% after 75 h. 
The release pattern indicated that the carrier responded quite well to GSH, a thiol-rich molecule. 
Drug release from the same formulations was 35% and 45% within 24 h and 72 h, respectively, 
in the presence of 0.1% wt. H2O2. Drug release was less than 10% in the redox-free buffer 
solution within 75 h. The results indicated that the diselenide bond incorporated in our structure 
showed more sensitivity toward the reductive than oxidative environments. Furthermore, PTX 
release from diselenide-containing micelles was negligible under redox-free conditions. In 
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addition, the drug release behavior of the PCL-(mPEG)2 micelles that lacked diselenide bonds 
was not affected by the redox environment (Fig. 5A). Cleavage of the diselenide bonds in the 
diselenide-containing micelles and shedding of the PEG shell along with aggregation of the PCL 
cores in the redox environment of a cancerous intracellular region resulted in a rapid PTX release 
compared to insensitive micelles and/or redox-free conditions. Furthermore, the stability of the 
micelles was monitored in 50% FBS (physiological condition). The size of PCL-(SeSe-mPEG)2 
particles incubated in 50% FBS for 20 days was measured by DLS. No significant change in size 
was observed (Fig. S6 A). Moreover, negligible release from PCL-(SeSe-mPEG)2 + PTX was 
detected in 50% FBS, which increased to 44% release within 60 hours by addition of 0.1% H2O2 
(Fig. S6 B). This result indicates that the carriers are stable under physiological conditions but 
release their payload when they are exposed to a redox environment.  
This finding indicated that the diselenide bonds in micelles would not cleave in normal PBS 
buffer but were a function of the GSH or H2O2 present in the buffer.  
 
3.5. Cytotoxicity and in vitro antitumor efficacy of micelles 
MTS assay was used to evaluate biocompatibility and cytotoxicity of the proposed nano-sized 
carriers against 4T1 cells. The cells were incubated with varying amounts of the micelle 
concentration for 24 h. Figure 5B shows that the blank nanocarriers, which included PCL-
(mPEG)2, PCL-(SeSe-mPEG)2, and PCL-(SeSe-PEG-FA)2, had very low cytotoxicities with 
greater than 80% viability at all the concentrations (0.01-1000 nM). The results indicated that all 
the blank nanocarriers were biocompatible, nontoxic, and suitable for use as delivery systems of 
anticancer agents. 
Cytotoxicity of diselenide- containing PTX-loaded micelles was dose dependent (Figure 5B and 
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Figure S7) (p<0.001) compared to the loaded nanocarrier that lacked diselenide. Data for the 
anticancer effect of the PTX-loaded PCL-(SeSe-PEG-FA)2 and PTX-loaded PCL-(SeSe-mPEG)2 
on 4T1 cells showed that PTX-loaded PCL-(SeSe-PEG-FA)2 had higher cytotoxicity even at 
PTX concentrations of 10 nM and lower compared to the PTX-loaded PCL-(mPEG)2 (p<0.001). 
This implied that carriers that contained diselenide bonds were responsive to redox stimuli 
present in the region and released PTX through active targeting. On the other hand, PTX-loaded 
PCL-(mPEG)2 micelles that lacked diselenide bonds did not have significant therapeutic effects 
in killing the cancerous cells.  
Compared to passive diffusion of Taxol

 through the cell membrane, the higher cytotoxicities of 
PTX-loaded PCL-(SeSe-PEG-FA)2 and PTX-loaded PCL-(SeSe-mPEG)2 have been attributed to 
the presence of diselenide and folate (p<0.001). Diselenide enhances targeted release of PTX in 
the cytoplasm of cancerous cells owing to its sensitivity to a thiol-rich and oxidative-rich 
environment. The improved toxicity of PTX-loaded PCL-(SeSe-PEG-FA)2 compared to the 
nonfolate targeted version was attributed to the higher binding affinity of folate-decorated 
micelles to folate receptor (FR)–expressing 4T1 breast cancer cells [53].  
We observed a greater cellular inhibition of PTX-loaded PCL-(SeSe-PEG-FA)2 compared to 
PTX-loaded PCL-(SeSe-mPEG)2 (p<0.05). At the 10 nM concentration, PTX-loaded PCL-
(SeSe-mPEG)2 reduced cell viability by approximately 50%, whereas PTX-loaded PCL-(SeSe-
PEG-FA)2 reduced cell viability by approximately 35% (P<0.01). We observed that PTX-loaded 
PCL-(SeSe-mPEG)2 killed half of the cells at the 10-nM concentration, whereas PTX-loaded 
PCL-(SeSe-PEG-FA)2 killed half of the cells at the 1 nM concentration. Compared to Taxol

, 
their IC50 values were 5.5-fold lower for PTX-loaded PCL-(SeSe-mPEG)2 and 55-fold lower for 
PTX-loaded PCL-(SeSe-PEG-FA)2. The results indicated that thiol- and oxidative-sensitive 
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PTX-loaded micelles demonstrated a higher antitumor effect in breast cancer cells compared to 
insensitive micelles and naked drug.  
 
3.6. Cellular uptake and distribution of drug-loaded micelles in 4T1 cells 
The therapeutic effects of drug-loaded micelles in cancer cells depend on internalization and 
sustained release of the carriers. Because PTX possesses no fluorescent characteristics to 
quantify the amount of intracellular uptake, we have used coumarin-6 as a hydrophobic 
fluorescent marker. We performed a time-course analysis (0.5 to 4 h) of couramin-6 uptake 
among different groups on 4T1 cells in the presence or absence of the micelles. Couramin-6 
uptake was analyzed by FACS (Fig. 6A(I)). We treated passage-2 4T1 cells with coumarin-6-
loaded PCL-(SeSe-mPEG)2, coumarin-6-loaded PCL-(SeSe-PEG-FA)2, and coumarin-6 (naked 
drug) at a drug concentration of 12.5 µg/mL. The control consisted of untreated 4T1 cells. There 
was a time-dependent increase in uptake from 0.5 to 4 h observed for all the micelle groups (data 
not shown). 4T1 cells showed the most uptake after 4 h. All other cell studies were conducted in 
folic acid–free media except for competition studies were folic acid was added at a concentration 
of 100 µg/ml. 
The mean fluorescence intensity (MFI) of 4T1 cells treated with coumarin-6-loaded PCL-(SeSe-
mPEG)2 and PCL-(SeSe-PEG-FA)2 was ~240 and ~719, respectively (Fig. 6A (II)). Because of 
the highly hydrophobic nature of coumarin-6, it readily partitioned into the lipid membranes and 
then diffused into the cells, which led to increased accumulation in these cells. We expected that 
owing to the increased expression of FR on 4T1 cells [54], the carriers that contained FA would 
have a higher internalization rate through FR. As shown in Figure 6A(I-II), cellular uptake of 
PCL-(SeSe-PEG-FA)2 was at an average of 2-fold greater than PCL-(SeSe-mPEG)2 micelles in 
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the 4T1cells. The uptake of PCL-(SeSe-PEG-FA)2 was reduced when the culture media were 
supplemented with free folic acid at a concentration of 100 µM (Fig. S8). These findings 
altogether confirmed the active targeting capacity of the synthesized micelles, which supported 
the results of earlier studies [55].  
 
Intracellular distribution of coumarin-6-loaded PCL-(SeSe-mPEG)2 and PCL-(SeSe-PEG-FA)2 
micelles (12.5 µg/mL drug concentration, 4 h) was visualized in cells by CLSM (Figure 6B). The 
fluorescence intensity of coumarin-6 in cells was qualitatively observed by CLSM. The results 
agreed with the flow cytometry results shown earlier, which confirmed that coumarin-6-loaded 
PCL-(SeSe-PEG-FA)2 had a stronger fluorescence intensity in the 4T1 cells than coumarin-6-
loaded PCL-(SeSe-mPEG)2. In the FA micelle–treated groups, coumarin-6 (green) was found 
densely dispersed around the blue nuclei (stained by DAPI), which implied that a higher number 
of fluorescently loaded micelles internalized into the 4T1 cells through the FR compared to the 
groups that lacked FA.  
The intracellular uptake and distribution of coumarin-6 of PCL-(SeSe-PEG-FA)2 was higher than 
that of PCL-(SeSe-mPEG)2 in 4T1 cells that overexpressed FR. These data demonstrated that the 
conjugated FA further enhanced the tumor cell targeting effect and cellular uptake of coumarin-
6-loaded PCL-(SeSe-PEG-FA)2 through FR-mediated endocytosis, which promoted the entry of 
coumarin-6-loaded PCL-(SeSe-PEG-FA)2 into FR-overexpressed 4T1 cells. In addition, based 
on the flow cytometry analysis (Fig. 6A(I)), we noted that the fluorescence intensity level of 
coumarin-6-loaded PCL-(SeSe-PEG-FA)2 was much brighter than that of coumarin-6-loaded 
PCL-(SeSe-mPEG)2. This confirmed that the FA-containing micelles were more efficiently 
internalized. 
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The cytotoxicity assays performed against 4T1 tumor cells with PTX-loaded micelles showed 
that PTX-loaded PCL-(SeSe-PEG-FA)2 had a higher killing effect than PTX-loaded PCL-(SeSe-
mPEG)2  in these cells. This was in agreement with the cell uptake results, which showed that 
because of the presence of FA, we had higher internalization of FA-conjugated micelles and a 
higher accumulation of PTX. This led to enhanced drug cytotoxicity against the 4T1 cells. 
 
3.7. In vivo antitumor effect 
The tumor targeting capability of a DDS is critical for improving its antitumor activity. We have 
evaluated the in vivo antitumor effect and targeting of the micelles in a xenograft 4T1 murine 
breast cancer model. Based on results obtained from the in vitro studies, the smart micelles 
demonstrated satisfactory results; hence, we proceeded further for in vivo experiments. Figure 
7A shows the progress of tumor volume growth during 30 days with different formulations of 
PTX-loaded smart micelles, free drug (Taxol®), and saline (control). Compared with the control 
and Taxol
®
 groups, the smart micelle-treated groups exhibited a slower growth rate in tumor 
volume. The two micelle groups had a better inhibitory effect against tumor growth than the 
other groups, even when drug injection was stopped (p<0.001).  
Remarkably, the average tumor volumes of the PTX-loaded PCL-(SeSe-PEG-FA)2 and PTX-
loaded PCL-(SeSe-mPEG)2 treated groups were significantly smaller than the volumes of the 
saline and Taxol
®
-treated groups on day 30. This could be attributed to an enhanced permeation 
and retention (EPR) effect of nano-sized micelle delivery systems [56, 57]. In addition, the 
passively targeted PTX-loaded PCL-(SeSe-PEG-FA)2 micelle that accumulated in the solid 
tumor region might be taken up more readily by 4T1 cells through a receptor-mediated 
endocytosis process. A combined effect of the passive targeting and enhanced cellular uptake 
  
30 
 
would be the main reason for the slow growth rate in tumors treated with PTX-loaded PCL-
(SeSe-PEG-FA)2. No statistically significant difference in antitumor effects between PTX 
micelles with or without FA was observed in the in vivo therapy study. One may propose that 
this may be due to the immature release of the drug from the micelles following i.p. injection. 
This hypothesis although cannot be disproven without conducting a 
pharmacokinetic/biodistribution experiment tracking both the free drug and the micelle to 
determine whether the micelles deliver the drug to the tumor and how much of the injected dose 
accumulates in the tumor, one can see the difference in histological analysis between the two 
groups, i.e., ~80% tumor tissue necrosis in the PTX-loaded PCL-(SeSe-PEG-FA)2+PTX group 
and ~64% for the PTX-loaded PCL-(SeSe-mPEG)2 group. A similar behavior in attaining 
significant differences in tumor sizes while changes at cellular levels could still occur has been 
observed in other studies using other types of tumors/carriers [58]. It is possible that the fast-
growing nature of this tumor type (doubling time: 14.2 hours) [59] surpasses the changes in 
biochemical/histological event among the treatment groups. There is less concern about the EPR 
effect of 4T1 tumors, as they have been proven leaky when testing other types of nanocarriers 
[60]. Future studies will attempt the intravenous injection to ensure that the micelles encounter 
less biological barriers before reaching the tumor by the EPR effect, e.g., interaction with high–
protein content i.p. fluids and drainage into lymphatic capillaries. 
Figure 7B shows the changes in body weight of the different mice groups, as a safety indication, 
during the therapeutic experiment. Each group was compared to itself (for example, the weight 
of the Taxol
®
 group was compared to that of the Taxol
®
 group at different time points) in terms 
of increase or decrease in weight. No significant reduction in body weight in the mice that 
received the PTX-loaded PCL-(SeSe-mPEG)2 and PTX-loaded PCL-(SeSe-PEG-FA)2 micelles 
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were observed, which indicated reasonable safety levels and minimum side effects of these 
formulations. On the other hand, mice that received free Taxol
®
 had evidence of weight loss 
during the treatment, and this might indicate adverse treatment effects and systemic toxicity.   
Significant tumor inhibition in the groups treated with PTX-loaded PCL-(SeSe-mPEG)2 and 
PTX-loaded PCL-(SeSe-PEG-FA)2 was observed. This finding supported the observed results 
from the in vitro tests. Figure 7A shows that no significant difference existed in tumor growth 
rate between the PTX-loaded PCL-(SeSe-PEG-FA)2 and PTX-loaded PCL-(SeSe-mPEG)2 
groups. H&E staining of tumors treated with folate micelles showed a high degree of necrosis 
and areas empty of cells (Fig. 9 A, B). This demonstrated that the antitumor effect of the active 
targeted system PTX-loaded PCL-(SeSe-PEG-FA)2 was stronger than those of PTX-loaded PCL-
(SeSe-mPEG)2 and Taxol
®
, which could be due to the combined effect of passive targeting 
through EPR- and FR-mediated enhanced intracellular delivery. Tumor growth was inhibited in 
both groups of smart micelles compared to the Taxol
®
-treated group which indicated that redox-
sensitive micelles led to a greater accumulation of Taxol
®
 in the tumor. 
In this study, the formulation was administrated through the i.p. route as a proof of concept 
study. Future studies will explore the i.v. route as a more clinically relevant route. Preliminary 
unpublished work demonstrated that these formulations did not result in mice death at the doses 
reported in this study. Additional work investigating the biocompatibility after i.v. injection is, 
however, still required. 
 
3.8. Histological investigation of organ damage 
H&E staining showed the presence of drug-related toxicities to the major organs in the PTX-
loaded PCL-(SeSe-PEG-FA)2– and PTX-loaded PCL-(SeSe-mPEG)2–treated groups compared 
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to the saline and Taxol
®
 groups on day 30. Figure 8 shows that the control group had liver and 
spleen damage. The Taxol
®
 group had damage to the liver, heart, spleen, and lungs. The control 
group had evidence of metastatic seeding of breast cancer cells in the liver, spleen histiocytosis, 
and depletion of lymph nodules. The Taxol
®
 group had evidence of the following damages to the 
heart (Zenker’s necrosis and atrophy of myocardial cells), kidneys (mild hyperemia), spleen 
(histiocytosis), lungs (thickening of the alveolar walls and inflammatory cell infiltration), and 
liver (metastatic seeding of breast cancer cells). By contrast, the PTX-loaded PCL-(SeSe-PEG-
FA)2– and PTX-loaded PCL-(SeSe-mPEG)2–treated groups had significantly less damage to the 
heart, lungs, liver, and spleen. These findings demonstrated the safety and therapeutic effect of 
the prepared micelles at the treated dose. 
  
3.9. Tumor histological and immunofluorescence analysis 
Histological and immunofluorescence analyses were performed on tumor tissues to further 
investigate the suppression efficiencies of PTX-loaded PCL-(SeSe-mPEG)2 and PTX-loaded 
PCL-(SeSe-PEG-FA)2. According to Figure 9A, H&E staining of normal 4T1 cells showed the 
presence of rhombic or polygonal cells and large purple nuclei with spherical or spindle shapes. 
The apoptotic cells shrank and turned into a round shape with condensed nuclei and became 
darker. Necrotic cell cytoplasm became a pink amorphous material, and the nucleus disappeared 
[61]. 
H&E results confirmed the in vivo antitumor effects of the micelle groups. Some degrees of 
apoptosis and necrosis were observed in the PTX-loaded PCL-(SeSe-PEG-FA)2 and PTX-loaded 
PCL-(SeSe-mPEG)2 tumor-treated groups. The folate-decorated micelles had larger necrotic 
areas in the tumor tissue, which indicated that these groups of micelles had better antitumor 
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effects compared to the control and Taxol

 groups. By contrast, Figure 9A shows the H&E-
stained tumor tissues from the control and Taxol
®
 groups. In these two groups, the tumor cells 
had large nuclei, a spherical shape, and high mitotic figures, and these indicated rapid tumor 
growth.  
The necrosis values for tumor tissues were less than 20% (p<0.001) for the Taxol
®
 and saline 
groups (Fig. 9B(I)). By contrast, there was 80% tumor tissue necrosis in the PTX-loaded PCL-
(SeSe-PEG-FA)2+PTX group and 64% for the PTX-loaded PCL-(SeSe-mPEG)2 group 
(p<0.001). These findings were in agreement with results of the previously reported antitumor 
effect. The micelles showed a better therapeutic effect of killing breast cancer cells and 
suppression of tumor growth than the naked drug. 
Ki-67 staining assay was performed to further investigate tumor suppression by this proliferation 
assay for the different treatment groups. As shown in Figure 9B(II), 86% of the control group 
expressed Ki-67 and 73% of the Taxol
®
 group expressed Ki-67 (p<0.001), which indicated 
active cell proliferation. PTX-loaded PCL-(SeSe-PEG-FA)2 and PTX-loaded PCL-(SeSe-
mPEG)2 groups showed less than 5% and 10% Ki-67 positive cells (p<0.05), respectively, thus 
suggesting reduced active cell proliferation and increased inhibition of tumor growth in the 
micelle groups compared to the control and Taxol
®
-treated groups. These results presented 
substantial evidence for the high antitumor activity of the smart micelle groups, particularly the 
PTX-loaded PCL-(SeSe-PEG-FA)2 group. 
 
3.10. Myelosuppression assay 
Bone marrow suppression is considered a serious toxicity of PTX [62]. Myelosuppression by 
micelles and PTX was evaluated by monitoring WBC counts before and after administration. As 
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shown in Figure S3A, Taxol
®
 induced a significant decrease in WBC levels from 10×10
3
/µL to 
4.2×10
3
/µL (p<0.001). Normal WBC levels range from 5-12×10
3
/µL for BALB/c mice [63]. 
Obviously, the WBC level in the Taxol
®
-treated group was lesser than the normal range. The 
WBC count in the PTX-loaded PCL-(SeSe-PEG-FA)2 and PTX-loaded PCL-(SeSe-mPEG)2 
groups did not decrease significantly. The mean WBC count of the PTX-loaded PCL-(SeSe-
PEG-FA)2 and PTX-loaded PCL-(SeSe-mPEG)2 treated group was 8.1×10
3
/µL, which was 
within the normal range.  
The results in Supplementary Figure S3B do not show a significantly abnormal increase in liver 
function tests (SGOT and SGPT) in groups treated by the micelles. However, the PTX-treated 
groups had a significant increase in SGOT and SGPT levels, which indicated a decrease in liver 
function. 
3.11. CT and ultrasound images 
 
CT images obtained from the groups treated with PTX and saline showed multiple well-defined 
sublumbar lymph node invasions with heterogeneous postcontrast enhancement. The PTX-
loaded PCL-(SeSe-mPEG)2 and PTX-loaded PCL-(SeSe-PEG-FA)2 groups did not show any 
significant metastatic lesions nor any lymph node invasion. The main lesions in the saline and 
Taxol

-treated groups (Fig. S4A) were subjectively larger and more heterogeneous in 
Hounsfield unit texture compared to the micelle-treated groups (Fig. S4C, D), which contained 
hypoattenuated lesions. 
Figure S4E, F show ultrasound (US) images for the groups treated with saline and Taxol

; 
multiple, well-defined homogenous, round-to-oval hypo-echo nodules up to 1 cm in length at the 
level of the subcutaneous lymph nodes were observed. By contrast, US images (Fig. S4G, H) for 
the PTX-loaded PCL-(SeSe-mPEG)2- and PTX-loaded PCL-(SeSe-PEG-FA)2-treated groups 
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showed no definite signs that were compatible with any mass lesion in the retroperitoneal and 
peritoneal regions. Additionally, the subcutaneously induced masses were subjectively smaller 
and more ill-defined compared to the saline and PTX-treated groups that had heterogeneous 
hypo- to anechoic echotextures.  
4. Conclusion 
In this study, a redox-sensitive shell-sheddable micelle based on a PCL-(SeSe-PEG-FA)2 triblock 
copolymer containing redox-sensitive linkages was successfully synthesized and characterized. The 
diselenide bonds, as redox-sensitive linkages, located between hydrophilic and hydrophobic 
segments resulted in the development of the shell-sheddable micelle. The micelles could incorporate 
a hydrophobic anticancer drug (PTX) into their hydrophobic core. The loaded drug was released by 
shedding of shell under redox conditions as opposed to drug diffusion. The micelles showed a higher 
cell internalization rate through FR-mediated endocytosis. The diselenide-containing micelles were found 
to have a better killing effect on 4T1 cells when tested in vitro compared to naked drug or insensitive 
micelles. The PTX-loaded micelles also showed a better antitumor effect and an inhibited tumor growth 
rate compared to micelles lacking diselenide, in female BALB/c 4T1 tumor-bearing mice. Despite the 
preliminary stage at which this system is currently in, considering advances made for Genexol and NK-
105 reaching clinical testing [64-65], the results depicted the potential of diselenide-containing smart 
micelles as delivery vehicles for a wide variety of diseases that have abnormal reductive or oxidative 
environments. We appreciate that costs for clinical studies will be added to the cost of this product; it is, 
however, estimated that this type of formulation would cost approximately 182$ for 30 mg/vial versus 
Genexol-PM (30 mg/vial) and PTX (30 mg/vial) costing 167.78 $ [66] and 163.4 $, respectively. The 
incremental cost effectiveness ratio of this smart carrier versus PTX is approximately 2,000 $ per year, 
which is above the per capita GDP in our country but in an acceptable range in Europe. Moreover, for the 
regulatory demands, because the block copolymers used in our study already have an FDA approval, our 
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only challenge would be obtaining approval for the smart bond. There are many details to be discussed 
and looked into, which requires further studies and tests. 
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Scheme legend 
 
Scheme 1. Schematic illustration of micelle formation and mechanism of drug release from 
responsive micelles in a redox environment of cancer cells. 
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Figure legends 
 
Fig. 1. Synthesis of diselenide (A) PCL-bis(SeSe-PEG)2 copolymers (B), and PCL bis(SeSe-
PEG-FA)2 (C). 
Fig. 2. 
77
Se-NMR (A) and 
1
H,
77
Se-HMBC (B)spectra of diselenide. 
 
Fig. 3. 
1
H-NMR spectra of 10-bromodecanoic acid (A), diselenide (B), (PCL-SeSe-COOH)2 (C), 
mPEG-OTS (D), m-PEG amine (E), and mPEG-(PCL-SeSe)2 (F).  
 
Fig. 4. Determination of the critical micelle concentration (CMC): Excitation spectra of pyrene 
in an aqueous solution of micelles at various concentrations (λemission: 372 nm) (I) and intensity 
ratio (I372/I384) as a function of micelle concentration (II) (A). Particle size and size distribution 
of micelles: Dynamic light scattering (DLS) of PCL-(SeSe-mPEG)2 and PCL-(mPEG)2 under 
different conditions (2 mM GSH, 0.1% wt. H2O2 and DPBS). Three batches for each micelle 
group with triplicates of each batch (3*3=9 set of tests for each group) were tested with DLS (B). 
Representative transmission electron microscopy (TEM) of micelles PCL-(SeSe-mPEG)2. Scale 
bar: 200 nm (C).  
 
Fig. 5. Cell survival and cumulative release of micelles. Time-dependent thiol-triggered and 
oxidative drug release of drug-loaded micelles in PBS, 0.1% wt. H2O2 and 2 mM GSH buffer at 
37∘C. Comparisons were made among diselenide containing micelles and PCL-(mPEG)+PTX 
(A). Cytotoxicity for 4T1 cells treated after 24 h with PCL-(mPEG)2, PCL-(SeSe-PEG-FA)2, 
PCL-(SeSe-mPEG)2, and antitumor activity of carriers versus the concentration of PTX for 4T1 
cells treated with Taxol
®
, PCL-(mPEG)2+PTX, PCL-(SeSe-PEG-FA)2+PTX, and PCL-(SeSe-
mPEG)2+PTX. PTX concentrations that caused inhibition of 50% cell viability (IC50 values) 
were determined by sigmoidal fitting as 55 nM for Taxol
®
, 1 nM for PCL-(SeSe-PEG-
FA)2+PTX, and 10 nM for PCL-(SeSe-mPEG)2+PTX. ***: PCL-(mPEG) +PTX vs. PTX, PCL-
(mPEG)+PTX vs. PCL-(SeSe-PEG-Folate)2+PTX, PCL-(mPEG)2+PTX vs. PCL-(SeSe-
mPEG)2+PTX; **: PCL-(mPEG)2+PTX vs. PCL-(SeSe-mPEG)2+PTX; ***: PCL-
(mPEG)2+PTX vs. PCL-(SeSe-mPEG)2+PTX (B). Each experiment was repeated thrice, and this 
is a representative of all. The IC50 value was calculated and analyzed by the Newman−Keuls test 
following one-way ANOVA. The data were expressed as mean ± SEM. Error bars are based on 
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three parallel samples. Plain micelles (without PTX) were nontoxic. *p<0.05, **p<0.01, ***p < 
0.001 (n=3). 
 
Fig. 6. Cellular uptake and distribution of drug-loaded micelles in 4T1 cells. Cellular uptake 
measured 4 h post-treatment by flow cytometry. The cells were treated with coumarin-6–loaded 
PCL-(SeSe-mPEG)2 and PCL-(SeSe-PEG-FA)2 as well as coumarin-6. Folate-conjugated 
micelles showed better cellular uptake (I). Comparison of qualitative cellular uptake efficiency 
between coumarin-6–loaded PCL-(SeSe-mPEG)2 and coumarin-6–loaded PCL-(SeSe-PEG-FA)2. 
Data are represented as mean ± SD (n=3) (II) (A). Cellular distribution of 4T1 cells 4 h post-
treatment with PCL-(SeSe-mPEG)2+coumarin-6 and PCL-(SeSe-PEG-FA)2+coumarin-6 using 
confocal laser scanning microscopy (CLSM). The cell nucleus was stained blue (DAPI), and the 
green stains were coumarin-6 (scale bar: 50 µm). We observed a higher cell uptake in the folate-
conjugated micelles (B). Each experiment was repeated thrice. The cellular uptake value was 
calculated and analyzed by the Newman−Keuls test following one-way ANOVA. The data were 
expressed as mean ± standard deviation. ***: p<0.001 (n=9).  
 
Fig. 7. Tumor growth inhibition and body weight changes in BALB/c 4T1 tumor-bearing mice. 
Mice received intraperitoneal (i.p.) injections with a 15 mg/kg PTX equivalent dose: PTX-loaded 
PCL-(SeSe-mPEG)2 and PCL-(SeSe-PEG-FA)2, control (saline), and Taxol
®
. The mice received 
six i.p. injections on days 0, 4, 8, 12, 16, and 20. We observed better therapeutic effects in 
diselenide-containing micelles than in the other treatment groups (A). Body weight changes in 
similar groups. There was no significant weight loss observed in mice treated with diselenide 
micelles compared to the other treatment groups. ***p<0.001 (*** and ****: micelles vs. the 
other two groups) (B). The data were analyzed by the Newman−Keuls test following one-way 
ANOVA. Tumor volume and weight values are represented as mean ± SEM. *p<0.05, **p<0.01, 
***p < 0.001 (n=6). 
 
Fig. 8. Histological assessments with hematoxylin and eosin (H&E) staining of vital organs from 
female BALB/c 4T1 tumor-bearing mice treated with intraperitoneal (i.p.) injections of Taxol
®
, 
PCL-(SeSe-mPEG)2+PTX, PCL-(SeSe-PEG-FA)2+PTX, and control (saline) (heart, kidneys, 
liver, spleen, and lungs). These are representative sections from five mice per group. The organs 
were harvested at day 30 post injection. We observed the following effects: Zenker’s necrosis, 
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mild hyperemia, myocardial atrophy, myofibrillar loss, and cell atrophy (black arrows). 
Histological analysis was conducted after H&E staining. Scale bar: 200 µm. 
 
Fig. 9. Hematoxylin and eosin (H&E) and Ki-67 staining analysis of tumor sections in female 
BALB/c 4T1 tumor-bearing mice treated with intraperitoneal (i.p.) injections of Taxol
®
, PCL-
(SeSe-mPEG)2+PTX, and PCL-(SeSe-PEG-FA)2+PTX. The cytoplasm stained light red by 
eosin, whereas the cell nucleus stained purple with hematoxylin (H&E staining). The green 
stains indicated Ki-67-positive staining areas and nuclei in the Ki-67 assay, respectively. Images 
are representative sections from five mice per group. The organs were harvested at day 30. Scale 
bar: 200 µm (A). Necrosis of the tumor tissue was quantified using H&E images (I). 
Proliferation of tumor cells was quantified using Ki-67 staining images (II) (*, **, ***: micelle 
groups compared to the control) (B). Necrosis of the tumor tissue and proliferation index were 
calculated and analyzed by the Newman−Keuls test following one-way ANOVA. Data were 
expressed as mean ± standard deviation. *p<0.05, **p<0.01, *** p<0.001. Data are represented 
as the mean ± SD (n=6).  
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On-demand drug actuation is highly desired. Redox-responsive polymeric DDSs have been 
shown to be able to respond and release their cargo in a selective manner when encountering a 
significant change in the potential difference, such as that present between cancerous and 
healthy tissues. This study offers an added advantage to the field of redox-responsive polymers 
by reporting a new type of shell-sheddable micelle based on an amphiphilic triblock co-
polymer, containing diselenide as a redox-sensitive linkage. The linkage was smartly located at 
the hydrophilic-hydrophilic bridge in the co-polymer offering complete collapse of the micelle 
when exposed to the right trigger. The system was able to delay tumor growth and reduce 
toxicity in a breast cancer tumor model following intraperitoneal injection in mice. 
 
 
  
 
